Visus Therapeutics
Biotechnology, 500 Yale Ave N, Seattle, Washington, 98109, United States, 11-50 Employees
Who is VISUS THERAPEUTICS
With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision f...
Read More
-
Headquarters: 500 Yale Ave N, Seattle, Washington, 98109, United States
-
Date Founded: 2019
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from VISUS THERAPEUTICS
Visus Therapeutics Org Chart and Mapping
Carmen Capeluto
Executive Assistant to Co-Founder, Cmo/Head of R&D and SVP, Business Development & Marketing
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Visus Therapeutics
Answer: Visus Therapeutics's headquarters are located at 500 Yale Ave N, Seattle, Washington, 98109, United States
Answer: Visus Therapeutics's official website is https://visustx.com
Answer: Visus Therapeutics's revenue is $10 Million to $25 Million
Answer: Visus Therapeutics's SIC: 2834
Answer: Visus Therapeutics's NAICS: 325412
Answer: Visus Therapeutics has 11-50 employees
Answer: Visus Therapeutics is in Biotechnology
Answer: Visus Therapeutics contact info: Phone number: Website: https://visustx.com
Answer: With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world. The company is developing novel miotic formulations for a once-daily eye drop to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration. Additionally, Visus Therapeutics has entered into a worldwide exclusive licensing agreement with DelSiTech Ltd, a leader in advanced, biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical benefit of ophthalmic therapies.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month